Acne
Conditions
Brief summary
This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of TVB-3567 administered orally in healthy participants. Part B will be a randomized, open-label, 2-way crossover investigation to assess the effect of food on a single dose TVB-3567 administered orally in healthy participants. Parts C and D will be randomized, double-blind, placebo-controlled investigations of multiple ascending doses (MAD) to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants without and with moderate to severe acne, respectively.
Interventions
DRUGTVB-3567
Orally administered capsule
DRUGPlacebo
Orally administered capsule
Sponsors
Sagimet Biosciences Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy Participants (Parts A, B and C) 1. Healthy, adult, male or female 18-55 years of age 2. Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 3. Medically healthy with no clinically significant medical history 4. Understands the study procedures in the informed consent form (ICF) and willing and able to comply with the protocol Healthy Participants with Acne (Part D only) Participants must meet all of the above criteria, as well as the following inclusion criteria to be eligible for participation in the study: 1. BMI ≥18.0 and ≤37.0 kg/m2. 2. Must be diagnosed with moderate to severe acne vulgaris
Exclusion criteria
Healthy Participants (Parts A, B and C) 1. History or presence of clinically significant medical or psychiatric condition or disease 2. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds including over the counter acne products. 3. Has a clinically significant ophthalmic examination finding 4. Female participant of childbearing potential 5. Unable to refrain from or anticipates the use of: * Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements * Any topical anti-acne treatment on the face * Any drugs known to be moderate or strong inducers of CYP3A4 enzymes, BCRP, and/or P gp, including St. John's Wort, beginning 28 days prior to the first dosing. * Part C only: Any previous tretinoin treatments, including tazarotene, adapalene, isotretinoin, and all-trans retinoic acid. Healthy Participants with Acne (Part D only) Participants must not be enrolled if they do not meet any of the above criteria, as well as the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A - Incidence of adverse events (AEs) and serious adverse events (SAEs) | Baseline to 7 to 8 days after dosing | — |
| Part B - Plasma AUC0-t in fasted and fed conditions | Baseline to Day 4 | Area under the concentration-time curve from time zero until the last observed concentration |
| Part B - Plasma AUC0-inf in fasted and fed conditions | Baseline to Day 4 | Area under the concentration-time curve from time zero to infinity |
| Part B - Plasma Cmax in fasted and fed conditions | Baseline to Day 4 | Maximum concentration measurement in plasma |
| Part B - Incidence of adverse events (AEs) and serious adverse events (SAEs) under fasted and fed conditions | Baseline to 7 to 8 days after dosing | — |
| Part C - Incidence of adverse events (AEs) and serious adverse events (SAEs) | Baseline to 13 to 15 days after the last dose | — |
| Part D - Incidence of adverse events (AEs) and serious adverse events (SAEs) | Baseline to 13 to 15 days after the last dose | — |
Countries
Australia, United States
Contacts
CONTACTStudy Director
Outcome results
None listed